Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10922273 | 0.91 | MEN1 (0.80) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL4746770 | 0.90 | MEN1 (0.63) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL16322249 | 0.89 | MEN1 (0.61) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL4378184 | 0.87 | KMT2A (0.83) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL853676 | 0.86 | MEN1 (0.65) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL7700654 | 0.86 | MEN1 (0.69) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL18660186 | 0.85 | MEN1 (0.68) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL15480439 | 0.85 | MEN1 (0.68) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL9018657 | 0.84 | MEN1 (0.71) | MEN1KMT2AMAPTHTTLMNA | |
| SCHEMBL3262054 | 0.83 | MEN1 (0.63) | MEN1KMT2AMAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| CN-102533185-A | Waterborne acrylate adhesive | UNIV ZHEJIANG TECHNOLOGY | 2012-07-04 | — | — | CN | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122667-A2 | UREYLENE DERIVATIVES | SCHOOL OF PHARMACY (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008062235-A1 | THERAPEUTIC G-QUADRUPLEX LIGANDS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062235-A1 | THERAPEUTIC G-QUADRUPLEX LIGANDS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2008-05-29 | — | — | WO | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| US-4394156-A | Novel N-phenyl-substituted N-heterocyclic compounds, their preparation and use in agents for regulating plant growth | CIBA-GEIGY CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
| US-4294606-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| US-4208202-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | MEN1 827/4885KMT2A 1721/4885MAPT 1103/4885 |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | MEN1 3722/4885KMT2A 257/4885MAPT 3624/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MEN1 4760/4885KMT2A 1386/4885MAPT 3484/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MEN1 4190/4885KMT2A 1097/4885MAPT 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.